<SEC-DOCUMENT>0001193125-17-204725.txt : 20170615
<SEC-HEADER>0001193125-17-204725.hdr.sgml : 20170615
<ACCEPTANCE-DATETIME>20170615162356
ACCESSION NUMBER:		0001193125-17-204725
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170613
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170615
DATE AS OF CHANGE:		20170615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pulmatrix, Inc.
		CENTRAL INDEX KEY:			0001574235
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461821392
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36199
		FILM NUMBER:		17913766

	BUSINESS ADDRESS:	
		STREET 1:		99 HAYDEN AVENUE
		STREET 2:		SUITE 390
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		(781) 357-2333

	MAIL ADDRESS:	
		STREET 1:		99 HAYDEN AVENUE
		STREET 2:		SUITE 390
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ruthigen, Inc.
		DATE OF NAME CHANGE:	20130411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d372233d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June&nbsp;13, 2017 </B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PULMATRIX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36199</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>46-1821392</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File No.)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>99 Hayden Avenue, Suite 390 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lexington, MA 02421 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (781)&nbsp;357-2333 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;13, 2017 (the &#147;Effective Date&#148;), Amit Munshi was appointed as a Class I director of the board of directors (the &#147;Board&#148;) and a
member of the audit committee of Pulmatrix, Inc. (the &#147;Company&#148;), to serve for a term expiring at the next annual meeting of the Company&#146;s stockholders at which the term of the Class I directors expires or until his successor is duly
elected and qualified, or his earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his appointment to the Board, Mr.&nbsp;Munchi was granted a stock
option on the Effective Date to purchase 8,800 shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;Common Stock&#148;) with (i)&nbsp;an exercise price equal to the fair market value of a share of Common Stock on the
date of grant, (ii)&nbsp;a term of ten years and (iii)&nbsp;one-fourth of the stock option vesting on the first anniversary of the date of grant and an additional 2.083% vesting on the last day of each of the thirty-six months that follow the first
anniversary of the date of grant, provided that Mr.&nbsp;Munshi is providing services to the Company through the applicable vesting dates and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity
Incentive Plan and the Company&#146;s standard form of stock option agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;15, 2017, the Company issued a press release announcing the appointment of
Mr.&nbsp;Munshi to the Board.&nbsp;A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated June 15, 2017.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PULMATRIX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: June&nbsp;15, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ William Duke, Jr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William Duke, Jr.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d372233dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g372233g87d17.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Amit D. Munshi Joins Pulmatrix&#146;s Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Mr.&nbsp;Munshi brings over 25 years of executive leadership experience in biotechnology and </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>pharmaceuticals to help Pulmatrix move through the next stage of company development. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEXINGTON, MA &#150; <U>Pulmatrix, Inc.</U> (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs for major lung diseases, has
announced the appointment of <U>Amit D. Munshi</U> to the Pulmatrix Board of Directors. Mr.&nbsp;Munshi is currently President and CEO of <U>Arena Pharmaceuticals</U>, a biopharmaceutical company developing small molecule therapeutics across a
number of important conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Munshi has extensive experience in biotechnology and pharmaceuticals with an over 25 year record of
accomplishments. Prior to Arena Pharmaceuticals, Mr.&nbsp;Munshi was previously the CEO of Epirus Biopharmaceuticals and held the same role at Percivia LLC (sold to Johnson&nbsp;&amp; Johnson). From 2005 to 2010, Mr.&nbsp;Munshi was the Chief
Business Officer and a co-founder of Kythera Biopharmaceuticals, which was later acquired by Allergan for $2.1 billion. Earlier in his career, Mr.&nbsp;Munshi held roles of increasing responsibility at Amgen globally in multiple product management,
general management and corporate development positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am excited to be joining the Board and helping in the Company&#146;s next stage of
growth,&#148; said Mr.&nbsp;Munshi. &#147;As a lifelong sufferer of pulmonary disease, I am deeply passionate about the Company&#146;s mission and innovative approach to treating the lungs with the iSPERSE technology.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Mr. Munshi brings a breadth of experience in our industry to the table including commercialization of products and business development,&#148; said
Pulmatrix CEO <U>Robert W. Clarke, Ph.D.</U> &#147;His previous successes at biotechnology and pharmaceutical companies will broaden the scope of our Board as we move into our next stage of company growth and development of our pipeline
programs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Munshi holds multiple undergraduate degrees from the University of California, Riverside, and an MBA from The Peter F. Drucker
Graduate School at the Claremont Graduate University. Mr Munshi currently serves on the Board of Cytrellis Biosystems, Inc., a privately held company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT PULMATRIX </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pulmatrix is a clinical stage
biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented <U>iSPERSE<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP></U> technology. The Company&#146;s product pipeline is
focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, a
proprietary inhaled itraconazole formulation that could benefit severe asthmatics and patients with rare disease like cystic fibrosis.&nbsp;Pulmatrix also has in-licensed a series of novel anti-inflammatory molecules that are in development for COPD
(PUR1800) and IPF (PUR5700). Pulmatrix&#146;s product candidates are based on iSPERSE&#153;, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing
systemic side effects to improve patient outcomes. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of
the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning the amount and use of proceeds the Company expects to receive from the sale of
the shares of common stock in the registered direct offering, the closing of the transaction described in this press release, which is subject to customary conditions, and other statements that are not statements of historical fact, and may be
identified by words such as &#147;anticipates,&#148; &#147;assumes,&#148; &#147;believes,&#148; &#147;can,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;forecasts,&#148; &#147;guides,&#148; &#147;intends,&#148; &#147;is
confident that&#148;, &#147;may,&#148; &#147;plans,&#148; &#147;seeks,&#148; &#147;projects,&#148; &#147;targets,&#148; and &#147;would,&#148; and their opposites and similar expressions are intended to identify forward-looking statements. The
Company cautions that such statements involve risks and uncertainties that may materially affect the Company&#146;s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and
information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, market and other conditions, the
satisfaction of customary closing conditions related to the registered direct offering of common stock, the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain
collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and
to obtain such funding on commercially reasonable terms; the Company&#146;s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain
key executives and scientists; and the ability to secure and enforce legal rights related to the Company&#146;s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the
Company, is set forth in the Company&#146;s filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed with the Securities and Exchange Commission on March&nbsp;10, 2017, as may be supplemented or amended by
the Company&#146;s Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Clarke, CEO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) 357-2333 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>rclarke@pulmatrix.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William Duke, CFO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) 357-2333 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>wduke@pulmatrix.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g372233g87d17.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g372233g87d17.gif
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M!@XB(2:&K9$%04 #$H;,ABVSF0490S2G*0$[7-,".F@")=[ '?$HH@Q-&"<
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@<K4#Q#K<(QFW10*P*H I)-?HCK>\YTWO>MN[W@$! #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
